The report by the Institute of Medicine and postmarketing surveillance.
Klein
D F
DF
New York State Psychiatric Institute, New York, NY 10032, USA. donaldk737@aol.com
D002986:Clinical Trials as Topic / Q000592:standards; D017277:Drug Approval; D005069:Evaluation Studies as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects* / Q000627:therapeutic use; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D011358:Product Surveillance, Postmarketing / Q000592:standards*; D018570:Risk Assessment; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D014229:Triazolam / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D006993:Hypnotics and Sedatives; D014229:Triazolam